Andrew Cheng - 03 Oct 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
President & CEO, Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
03 Oct 2022
Net transactions value
-$326,128
Form type
4
Filing time
05 Oct 2022, 08:55:20 UTC
Previous filing
15 Sep 2022
Next filing
02 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $6,150 +10,000 +3.2% $0.6150* 320,148 03 Oct 2022 Direct F1
transaction AKRO Common Stock Sale $149,240 -4,550 -1.4% $32.80 315,598 03 Oct 2022 Direct F1, F2
transaction AKRO Common Stock Sale $179,600 -5,350 -1.7% $33.57 310,248 03 Oct 2022 Direct F1, F3
transaction AKRO Common Stock Sale $3,439 -100 -0.03% $34.39 310,148 03 Oct 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -10,000 -4.2% $0.000000 230,868 03 Oct 2022 Common Stock 10,000 $0.6150 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 2, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.28 to $33.25, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.28 to $34.00, inclusive.
F4 The options are vested and currently exercisable.